People · Operator
Named in public records as an officer, director or promoter · active 2008–2024 · Biotechnology, Other Health Care, Other, Other Technology, Energy / Climate
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Miragen Therapeutics, Inc. | — | Biotechnology | Series C | $197.8M | $3.3B | 2008 |
| ArcherDX, Inc. | — | Other Health Care | Series C | $115.1M | $35.6M | 2018 |
| Bioptix Diagnostics, Inc. | — | Other | Series A | $28.0M | $37.3M | 2011 |
| Ambrosia Biosciences Inc. | — | Biotechnology | Series A | $12.5M | $63.7M | 2024 |
| LineRate Systems, Inc. | — | Other Technology | Series A | $6.3M | $27.7M | 2011 |
| ProFoldRX, Inc. | — | Biotechnology | Seed | $4.3M | $75.5M | 2010 |
| Black Bear Energy, Inc. | — | Energy / Climate | Seed | $4.3M | $27.6M | 2016 |
| Centerstone Technologies Inc | — | Other Technology | Pre-Seed | $1.7M | $5.3M | 2009 |
| Hiberna Corp | — | Biotechnology | Pre-Seed | $100K | $5.5M | 2009 |
Kyle Lefkoff at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Kyle Lefkoff on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.